Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Generalized Myasthenia Gravis Clinical Trials

21 recruiting trials for Generalized Myasthenia Gravis. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
21
Total Trials
21
Recruiting Now
7
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 3NCT06463587

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized...

The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in...

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyEnrolling: 26420 locations
RECRUITINGNCT06064695

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

During this pilot study, the investigators will examine the effects of whole-body electrical muscle stimulation exercise (WB-EMS Exercise) on neuromuscular junction (NMJ)...

Sponsor: University of Missouri-ColumbiaEnrolling: 162 locations
RECRUITINGPhase 2NCT06987539

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With...

The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and...

Sponsor: AmgenEnrolling: 151 location
RECRUITINGPhase 1 / Phase 2NCT06704269

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a...

Sponsor: Novartis PharmaceuticalsEnrolling: 1510 locations
RECRUITINGPhase 3NCT06456580

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.

Sponsor: Vor BiopharmaEnrolling: 18020 locations
RECRUITINGPhase 2 / Phase 3NCT06392386

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric...

Sponsor: argenxEnrolling: 1220 locations
RECRUITINGPhase 3NCT06517758

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants...

The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG...

Sponsor: Novartis PharmaceuticalsEnrolling: 14620 locations
RECRUITINGPhase 2 / Phase 3NCT06055959

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study...

Sponsor: UCB Biopharma SRLEnrolling: 89 locations
RECRUITINGPhase 2NCT07284420

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With...

This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work...

Sponsor: argenxEnrolling: 705 locations
RECRUITINGNCT04202341

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion...

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 50020 locations
RECRUITINGPhase 3NCT06607627

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 1213 locations
RECRUITINGPhase 2 / Phase 3NCT06149559

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with...

Sponsor: UCB Biopharma SRLEnrolling: 1213 locations
RECRUITINGPhase 3NCT06587867

Seronegative Myasthenia Gravis - Efgartigimod IV

This is to study the efficacy, safety and tolerability of efgartigimod in patients with seronegative generalized myasthenia gravis. This is an open label study. There will be 30...

Sponsor: University Health Network, TorontoEnrolling: 301 location
RECRUITINGPhase 3NCT07039916

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.

Sponsor: Immunovant Sciences GmbHEnrolling: 23120 locations
RECRUITINGPhase 3NCT06744920

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With...

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care...

Sponsor: Novartis PharmaceuticalsEnrolling: 18020 locations
RECRUITINGPhase 2 / Phase 3NCT06193889

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis

Sponsor: Kyverna TherapeuticsEnrolling: 6614 locations
RECRUITINGPhase 2 / Phase 3NCT06447597

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.

Sponsor: Shanghai Jiaolian Drug Research and Development Co., LtdEnrolling: 10418 locations
RECRUITINGPhase 1NCT07215650

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Generalized Myasthenia...

Sponsor: Candid TherapeuticsEnrolling: 441 location
RECRUITINGNCT07294170

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in...

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best...

Sponsor: argenxEnrolling: 705 locations
RECRUITINGNCT06967480

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

The primary objective of the study is to evaluate the effectiveness of Ravulizumab in improving MG-ADL in an early-stage AChR+ gMG population.

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 4020 locations
RECRUITINGPhase 2 / Phase 3NCT04833894

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children...

The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG....

Sponsor: argenxEnrolling: 1220 locations